The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

Abstract

Sir, With reference to the study by Ward et al (2006), the article compares the cost effectiveness of oral fluoropyrimidine treatment for mCRC vs intravenously administered therapies. In particular, this paper compares Uftoral s (tegafur-uracil), with capecitabine, based on unit costs for drugs as outlined in the British National Formulary, 2002. However, there are a number of discrepancies we would like to highlight with this assessment. First, as of March 2006 the price of Uftoral s (tegafur-uracil) was reduced as indicated in the following table: